Ultragenyx is trading 4.23% down at $25.13 amid a broader biotech pullback and weak risk sentiment across U.S. equities.
- Ultragenyx announced accelerated FDA approval for GENGLYCOS on August 19, its first gene-therapy approval.
- That positive catalyst is not explaining today’s decline.
- Investors may be taking profits while biotech shares retreat and awaiting further commercialization details.